Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc ACHFF


Primary Symbol: V.ARCH

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

Bullboard (TSXV:ARCH)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by Riverfolkon Jun 07, 2022 10:30am

Arch Biopartners - My Due Diligence

Arch Biopartners Inc. (“Arch” or the “Company”) is a portfolio-based biotechnology company focused on the development of innovative technologies that have the potential to make a significant medical ...more  
327
Discussion
Post by Riverfolkon Apr 18, 2022 10:08am

Arch - Phase III Human Clinical Trial

https://www.archbiopartners.com/our-science/metablok/
257
Post by Riverfolkon Apr 18, 2022 9:49am

Current Market Cap Industry Peers:

Arch - $253,000,000 @ $4.07  Positive Phase II Data ( Organ Inflammation ) BLU - $1,100,000,000 @ $10.40 Positive Phase II Data ( Chronic Cough ) (NASDAQ) TRIL - $2,300,000,000 @ $22 Positive ...more  
148
Post by Riverfolkon Apr 18, 2022 9:49am

Arch Biopartners - My Due Diligence

Arch Biopartners - My Due Diligence Arch Biopartners Inc. (“Arch” or the “Company”) is a portfolio-based biotechnology company focused on the development of innovative technologies that have the ...more  
200
Comment by futuregainson Apr 04, 2022 12:48pm

RE:RE:Arch - Fully Funded Phase III Clinical Trial

It's true Riverfolk does repost a lot. BUT, to suggest this iis a p&d stock is inaccurtae. This company actually has a stage 3 clinical trial going on. We are all waiting for the results. Stay ...more  
172
Discussion
Comment by williepokeron Apr 04, 2022 11:26am

RE:Arch - Fully Funded Phase III Clinical Trial

Another pump and dump from Riverfolk
133
Discussion
Post by Riverfolkon Apr 04, 2022 9:21am

Arch - Fully Funded Phase III Clinical Trial

ClinicalTrial.gov CATCO LSALT PHASE III
222
Discussion
Post by Riverfolkon Mar 21, 2022 12:04pm

Arch - Dramatically Undervalued in comparison to its peers

Current Market Cap Industry Peers: Arch - $223,000,000 @ $3.60  Positive Phase II Data ( Organ Inflammation ) BLU - $819,000,000 @ $7.70 Positive Phase II Data ( Chronic Cough ) (NASDAQ)  ...more  
227
Post by Riverfolkon Mar 17, 2022 11:51am

Arch - Dramatically Undervalued in comparison to its peers

Current Market Cap Industry Peers: Arch - $219,000,000 @ $3.55  Positive Phase II Data ( Organ Inflammation ) BLU - $819,000,000 @ $7.70 Positive Phase II Data ( Chronic Cough ) (NASDAQ) TRIL  ...more  
193
Post by Riverfolkon Mar 17, 2022 10:03am

Arch - Motley Fool - Retirement Planning

Retirement Planning: 3 Unusual Bets That Could Pay Off Huge
167
Post by Riverfolkon Mar 16, 2022 11:10pm

Arch Biopartners - My Due Diligence (NEW)

Arch Biopartners Inc. (“Arch” or the “Company”) is a portfolio-based biotechnology company focused on the development of innovative technologies that have the potential to make a significant medical ...more  
514
Discussion
Post by Riverfolkon Mar 12, 2022 9:26am

Alberta-based research may have breakthough on kidney treatm

Alberta-based research may have breakthrough on kidney treatment
197
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities